2025年欧洲泌尿外科协会（EAU）大会上的临床数据展示强调了在膀胱癌诊疗中使用蓝光膀胱镜的优势-动脉网

Clinical data presentations at the European Association of Urology (EAU) 2025 congress highlight the benefits of using Blue Light Cystoscopy in bladder cancer

CISION 等信源发布 2025-03-25 01:23



可切换为仅中文







OSLO, Norway

挪威奥斯陆

，

March 24, 2025

2025年3月24日

/PRNewswire/ --

Photocure ASA

(OSE: PHO),

（OSE：PHO），

the Bladder Cancer Company, announces two abstract presentations at the 2025 European Association of Urology congress (EAU) in

膀胱癌公司宣布将在2025年欧洲泌尿外科协会大会（EAU）上进行两次摘要展示。

Madrid, Spain

西班牙，马德里

, highlighting the benefits of Blue Light Cystoscopy (BLC

，重点介绍了蓝光膀胱镜检查（BLC）的好处

), notably its impact on recurrence risk and ability to help urologists make the best bladder cancer management choices for their patients.

），特别是其对复发风险的影响以及帮助泌尿科医生为患者做出最佳膀胱癌管理选择的能力。

The EAU annual meeting is one of the largest international meetings in the urology calendar, showcasing the latest and most relevant clinical and scientific advancements in this area of patient care. This year's event was held on

欧洲泌尿外科学会年会是泌尿外科领域规模最大的国际会议之一，展示了该患者护理领域的最新和最相关的临床及科学进展。今年的会议于

March 21-24, 2025

2025年3月21日至24日

, and attracted urologists from all over the world. Photocure participated with its Hexvix

，吸引了世界各地的泌尿科医生。Photocure公司携其产品Hexvix参与其中。

product designed for better detection and resection of bladder tumors under the theme that 'Seeing is believing'. As in the past two years, Photocure will make 2025 EAU bladder cancer session highlights available to healthcare professionals after the event, by means of video interviews with the presenters of these sessions at the Photocure booth B28.

产品设计用于更好地检测和切除膀胱肿瘤，主题是“眼见为实”。在过去的两年中，Photocure将在2025年欧洲泌尿外科协会（EAU）膀胱癌会议结束后，通过在Photocure展位B28对这些会议的演讲者进行视频采访，向医疗专业人员提供会议亮点。

This successful initiative is once again supported by two of the leading names in Bladder Cancer in .

这一成功的举措再次得到了膀胱癌领域两位领军人物的支持。

Europe

欧洲

, Prof. M. Rouprêt, APHP, Sorbonne University

，M. Rouprêt教授，APHP，索邦大学

Paris, France

法国巴黎

and Prof.

和教授。

P. Gontero

P. 贡特罗

, Division of Urology, University of Studies of

泌尿外科部，研究大学

Torino, Italy

意大利都灵

。

In addition to this educational activity, the EAU scientific program prominently features Photocure's Hexvix product and/or the blue light cystoscopy procedure in which it is used. In particular, two notable abstract presentations were:

此外，EAU科学计划显著展示了Photocure的Hexvix产品和/或其应用的蓝光膀胱镜检查程序。特别是，两个显著的摘要报告是：

The impact of PDD on recurrence and progression in BCG-treated NMIBC* patients: a nationwide follow-up study

PDD对BCG治疗的NMIBC*患者复发和进展的影响：一项全国性随访研究

(Abstract session 39:

（摘要会议 39：

Sunday, March 23

3月23日，星期日

随机

，

5:15pm CET

下午5点15分，欧洲中部时间

– NMIBC: Advances in diagnosis and follow-up)

– 非肌层浸润性膀胱癌（NMIBC）：诊断与随访的进展

This nationwide cohort study investigates the association of PDD on recurrence and progression risk in BCG-treated NMIBC patients, using Danish registry data from 2009-2022 assessing patients treated with BCG for primary NMIBC.

这项全国性队列研究利用2009年至2022年的丹麦登记数据，调查了PDD对接受BCG治疗的非肌层浸润性膀胱癌（NMIBC）患者复发和进展风险的影响，评估了因原发性NMIBC接受BCG治疗的患者。

In the study, 4318 patients from the Danish registry were identified with a first-time NMIBC diagnosis that were treated with BCG. Of the study subjects, 2388 (55%) of patients were diagnosed with the assistance of PDD. Basic demographics, stage and grade was comparable between the two groups. There were no differences in BCG-response across exposure groups.

在该研究中，从丹麦登记处确定了4318名首次诊断为NMIBC并接受BCG治疗的患者。在研究对象中，有2388名（55%）患者是在PDD的辅助下诊断的。两组之间的基本人口统计学特征、分期和分级相似。在不同暴露组之间，BCG反应没有差异。

Age adjusted relative risk of recurrence was 0.88 (0.79 – 0.97) and 0.97 (0.89 – 1.05) at 1 and 5 years, respectively for the PDD-group compared to the non PDD-group. Age adjusted relative risk for progression was 0.93 (0.73 – 1.19) and 1.01 (0.84 – 1.21) at 1 and 5 years, respectively for the PDD-group..

年龄调整后的复发相对风险在1年和5年时，PDD组相对于非PDD组分别为0.88（0.79 – 0.97）和0.97（0.89 – 1.05）。对于进展的年龄调整相对风险，在1年和5年时，PDD组分别为0.93（0.73 – 1.19）和1.01（0.84 – 1.21）。

The authors conclude that, since the BCG-response across exposures were equal, the reduced risk of recurrence at 1 year was likely due to the detection effect of PDD: 'The present study did not support the hypothesis of PDD modulating the BCG-response in NMIBC patients, suggesting a different mechanism for the impact of PDD on recurrence and progression in BCG-treated NMIBC patients.'.

作者得出结论认为，由于跨暴露的BCG反应相同，1年复发风险的降低很可能是由于PDD的检测效应：“本研究并不支持PDD调节NMIBC患者BCG反应的假设，这表明PDD对接受BCG治疗的NMIBC患者的复发和进展的影响机制可能不同。”

Read the abstract:

阅读摘要：

https://urosource.uroweb.org/resource-centres/EAU25/262112/abstract

https://urosource.uroweb.org/resource-centres/EAU25/262112/摘要

Trans Urethral Laser Ablation of bladder tumors under local anesthesia: A prospective study of pain and recurrences

局部麻醉下经尿道激光消融膀胱肿瘤：疼痛与复发的前瞻性研究

(Abstract session 50:

（摘要会议 50：

Monday, March 24

3月24日，星期一

泰国

，

12:30pm CET

中午12:30（欧洲中部时间）

– NMIBC: Innovations and outcomes 2)

– 非肌层浸润性膀胱癌：创新与成果 2)

This study investigated the short- and long-term oncology safety regarding recurrence and progression as well as perioperative pain after office-based Transurethral Laser Ablation (TULA) or fulguration by PDD-assisted flexible cystoscopy.

本研究调查了在办公室进行的经尿道激光消融术（TULA）或光动力诊断辅助的软性膀胱镜下烧灼术后的短期和长期肿瘤学安全性，包括复发和进展以及围手术期疼痛。

This prospective observational study enrolled eligible patients from

这项前瞻性观察性研究纳入了符合条件的患者

August 2017

2017年8月

至

June 2022

2022年6月

在

Oslo University

奥斯陆大学

Hospital. 329 patients were enrolled, with a median age of 74 years. The median NRS (numeric rating scale) for perioperative pain was 4 (IQR: 3-5) for both the laser and fulguration group. The 12-month relapse-free survival (RFS) was 91% overall, 93% for fulguration, and 89% for laser ablation. The 12-month PFS was 94% for the laser group and 97% for the fulguration group..

医院。共纳入329名患者，中位年龄为74岁。激光组和电灼组的围手术期疼痛中位数值评分量表（NRS）均为4（四分位距：3-5）。整体12个月无复发生存率（RFS）为91%，电灼组为93%，激光消融组为89%。激光组12个月无进展生存率（PFS）为94%，电灼组为97%。

The authors conclude that office-based TULA under local anesthesia using PDD-assisted flexible cystoscopy is associated with low perioperative pain and does not compromise short- or long-term RFS or PFS. Therefore, it is a feasible option regarding perioperative pain and oncological safety.

作者得出结论，在局部麻醉下使用PDD辅助的柔性膀胱镜进行办公室内的TULA与较低的围手术期疼痛相关，并且不会影响短期或长期的RFS或PFS。因此，就围手术期疼痛和肿瘤学安全性而言，它是一个可行的选择。

Read the abstract:

阅读摘要：

https://urosource.uroweb.org/resource-centres/EAU25/262903/abstract

https://urosource.uroweb.org/resource-centres/EAU25/262903/摘要

'These new study data presented at EAU continue to emphasize the importance of using Blue Light Cystoscopy in the diagnostic pathway for bladder cancer. Minimally invasive procedures are on the rise and these abstracts also address data gaps in the long-term use of BLC in high-risk patients, where accurate staging determines all further treatment decisions', .

“这些在欧洲泌尿外科协会上公布的新研究数据继续强调了在膀胱癌诊断路径中使用蓝光膀胱镜的重要性。微创手术正在兴起，这些摘要还解决了在高风险患者中长期使用蓝光膀胱镜的数据空白，其中准确的分期决定了所有后续治疗决策。”

said Anders Neijber, Chief Medical Officer of Photocure.

Photocure首席医学官安德斯·内伊伯表示。

'BLC has been shown to clinically increase TURBT quality, more accurately stage disease, and enable better recurrence monitoring to help improve the lives of patients with bladder cancer.'

'BLC已被临床证明可以提高TURBT的质量，更准确地分期疾病，并实现更好的复发监测，从而帮助改善膀胱癌患者的生活。'

During the EAU Congress, on

在欧洲泌尿外科协会大会期间，

March 21

3月21日

, Photocure, in collaboration with Olympus, also hosted a well-attended scientific event on 'Precision Imaging in Bladder Cancer: Focus on Blue Light Cystoscopy'. The event, chaired by Ms.

，Photocure与奥林巴斯合作，还举办了一场备受关注的科学活动，主题为“膀胱癌的精准成像：聚焦蓝光膀胱镜检查”。该活动由女士主持。

Bernadett Szabados

伯纳黛特·萨博迪

(UCLH,

（UCLH，

London, UK

英国伦敦

) and Professor

）和教授

Christian Beisland

克里斯蒂安·贝斯兰德

(Haukeland University Hospital,

（豪克兰大学医院，

Bergen, Norway

挪威卑尔根

), brought together leading experts who exchanged insights on the importance of advanced imaging technologies in urology. This collaboration between Photocure and Olympus underscores a shared commitment to innovation in cancer imaging and improving patient outcomes.

），汇集了领先的专家，他们就先进成像技术在泌尿科中的重要性交流了见解。Photocure与Olympus之间的合作凸显了双方在癌症成像创新和改善患者预后方面的共同承诺。

*NMIBC: Non-muscle invasive bladder cancer

*NMIBC：非肌层浸润性膀胱癌

**TURBT: trans-urethral resection of bladder tumors

经尿道膀胱肿瘤切除术 (TURBT)

Note to editors:

编辑注意：

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

本发布中提到的所有商标均受法律保护，并且是Photocure ASA的注册商标。

This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin..

本新闻稿可能包含在您所在的国家无效或无法获取的产品详细信息和信息。请注意，Photocure 对访问此类可能不符合您所在国家的任何法律程序、法规、注册或使用的资讯不承担任何责任。

About Bladder Cancer

关于膀胱癌

Bladder cancer ranks as the 8

膀胱癌排名第8位

第

most common cancer worldwide – the 5

全球最常见的癌症——第五

most common in men – with 1 949 000 prevalent cases (5-year prevalence rate)

在男性中最常见——有1,949,000例普遍病例（5年患病率）

, 614 000 new cases and more than 220 000 deaths in 2022.

，2022年新增614,000例病例和超过220,000例死亡。

Approx. 75% of all bladder cancer cases occur in men.

大约75%的膀胱癌病例发生在男性身上。

It has a high recurrence rate with up to 61% in year one and up to 78% over five years.

它的复发率很高，一年内复发率高达61%，五年内复发率高达78%。

Bladder cancer has the highest lifetime treatment costs per patient of all cancers.

膀胱癌是所有癌症中每位患者终生治疗费用最高的。

Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike.

膀胱癌是一种代价高昂、可能逐步进展的疾病，由于复发风险高，患者需要接受多次膀胱镜检查。迫切需要改进膀胱癌的诊断和管理，以造福患者和医疗系统。

。

Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions.

膀胱癌根据其在膀胱壁内侵袭的深度分为两类：非肌层浸润性膀胱癌（NMIBC）和肌层浸润性膀胱癌（MIBC）。NMIBC停留在膀胱内衬细胞的内层，这些癌症占所有膀胱癌病例的75%，包括Ta、原位癌（CIS）和T1病变等亚型。

In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat..

在肌层浸润性膀胱癌 (MIBC) 中，癌症已侵入膀胱壁的更深层。这些癌症，包括 T2、T3 和 T4 亚型，更容易扩散且更难治疗。

Globocan. a) 5-year prevalence / b) incidence/mortality by population. Available at:

全球癌症观察站。a) 5年患病率 / b) 按人口计算的发病率/死亡率。可用资源：

https://gco.iarc.fr/today

, accessed [

，访问 [

February 2024

2024年2月

Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657

Babjuk M, 等。《欧洲泌尿外科杂志》。2019年；76(5): 639-657

Sievert KD et al. World J Urol 2009;27:295–300

Sievert KD 等。《世界泌尿外科杂志》2009年；第27卷：295-300页

Bladder Cancer. American Cancer Society.

膀胱癌。美国癌症协会。

https://www.cancer.org/cancer/bladder-cancer.html

About Hexvix

关于Hexvix

/Cysview

(hexaminolevulinate HCl)

（盐酸己氨基乙酰丙酸）

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the bladder, making them glow bright pink during Blue Light Cystoscopy (BLC

Hexvix/Cysview是一种优先积聚在膀胱癌细胞中的药物，在蓝光膀胱镜检查（BLC）中使它们呈现亮粉红色。

). BLC with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves the detection of tumors and leads to more complete resection, fewer residual tumors, and better management decisions.

). 与单独使用标准白光膀胱镜相比，使用Hexvix/Cysview的BLC改善了肿瘤的检测，导致更完全的切除、更少的残留肿瘤以及更好的管理决策。

Cysview is the tradename in the U.S. and

Cysview 是美国的商标名称，和

Canada

加拿大

, Hexvix is the tradename in all other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S. and

，Hexvix 是其他所有市场的商品名。Photocure 正在美国直接推广 Cysview/Hexvix，并且

Europe

欧洲

and has strategic partnerships for the commercialization of Hexvix/Cysview in

且在商业化Hexvix/Cysview方面拥有战略合作伙伴关系，

China

中国

，

Chile

智利

，

Australia

澳大利亚

，

New Zealand

新西兰

and

和

Israel

以色列

. Please refer to

请参阅

https://photocure.com/partners/our-partners

for further information on our commercial partners.

获取有关我们商业合作伙伴的更多信息。

About Photocure ASA

关于Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in

Photocure：膀胱癌公司提供变革性的解决方案，以改善膀胱癌患者的生活。我们独特的技术使癌细胞发出亮粉色的光，已为全球患者带来了更好的健康结果。Photocure 总部位于

Oslo, Norway

挪威奥斯陆

and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at

并在奥斯陆证券交易所上市（OSE：PHO）。欲了解更多信息，请访问我们网站

www.photocure.com/news

CONTACT:

联系：

For further information, please contact:

如需更多信息，请联系：

Dan Schneider

丹·施耐德